The University of Hong Kong's Wang Weiping team ANBR: Using photopharmacological technology to control immunotherapy

Keywords: immunotherapy, photopharmacology, PD-L1 dimerization, light-responsive prodrugs

Figure 1.

Tumor immune escape is a classic feature of the tumor microenvironment

At present, the clinical drugs used to inhibit the PD-1/PD-L1 pathway are mainly monoclonal antibodies

However, non-selective activation of the immune system can lead to toxic side effects of overly-immune T cells on normal tissues

Figure 2.

[7-(diethylamino)coumarin-4-yl]methyl (DEACM), as a commonly used PPGs, has the advantages of fast photocleavage reaction and relatively few by-products

Figure 3.

Figure 4.

The authors then further verified that the released BMS-1 ​​can successfully block the PD-1/PD-L1 interaction, allowing T cells to restore immune function and release cytokines

WILEY

Paper information:

Optochemical Control of Immune Checkpoint Blockade via Light-Triggered PD-L1 Dimerization

Yuwei Liu, Kaiqi Long, Weirong Kang, Tianyi Wang, and Weiping Wang

Advanced Nanobiomed Research

DOI: 10.

Click "Read the original text" in the lower left corner to view the original text of the paper

Advanced

NanoBiomed

Research

Journal Introduction

Advanced NanoBiomed Research (ANBR) aims to provide a publishing platform for nanomedicine, bioengineering and biomaterials research to improve human health, focusing on the application of these fields in disease diagnosis and treatment, and expects to be the flagship of the Advanced series in the biomedical field.

AdvancedScienceNews

Wiley's official WeChat platform for scientific research information

Long press the QR code to follow us

Share cutting-edge information｜Focus on scientific research trends

To publish scientific research news or apply for information sharing, please contact: ASNChina@Wiley.
com